Type 2 Diabetes - Pipeline Review, H2 2013


Naperville, IL -- (SBWIRE) -- 09/09/2013 -- Reportstack, provider of premium market research reports announces the addition of Type 2 Diabetes - Pipeline Review, H2 2013 market report to its offering
Type 2 Diabetes - Pipeline Review, H2 2013


, 'Type 2 Diabetes - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Type 2 Diabetes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Type 2 Diabetes. Type 2 Diabetes - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Type 2 Diabetes.
- A review of the Type 2 Diabetes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Type 2 Diabetes pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Bristol-Myers Squibb Company
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Shionogi & Co., Ltd.
Medinox, Inc.
Amgen Inc.
Eli Lilly and Company
GlaxoSmithKline plc
MedImmune LLC
Isis Pharmaceuticals, Inc.
Gilead Sciences, Inc.
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
Dainippon Sumitomo Pharma Co., Ltd.
Taisho Pharmaceutical Co., Ltd.
Euroscreen S.A.
Novo Nordisk A/S
Generex Biotechnology Corporation
Takeda Pharmaceutical Company Limited
FibroGen, Inc.
Ipsen S.A.
Piramal Healthcare Limited
Nycomed International Management GmbH
Neurocrine Biosciences, Inc.
Teijin Pharma Limited
Novartis AG
Astellas Pharma Inc.
Biocon Limited
Chong Kun Dang Pharmaceutical
Chugai Pharmaceutical Co. Ltd
Dong-A Pharmaceutical Co., Ltd.
Forest Laboratories, Inc.
Glenmark Pharmaceuticals Ltd.
Ildong Pharmaceutical Co., Ltd.
Japan Tobacco Inc.
Kissei Pharmaceutical Co., Ltd.
Les Laboratoires Servier
Mitsubishi Tanabe Pharma Corporation
Pfizer Inc.
Ranbaxy Laboratories Limited
Sigma-Tau S.p.A.
Zydus Cadila Healthcare Limited
Hadasit Medical Research Services & Development Ltd
Biodel Inc.
Bayer AG
Zosano Pharma, Inc.
MannKind Corporation
Halozyme Therapeutics
Merck KGaA
Alchemia Limited
Addex Pharmaceuticals
Evotec Aktiengesellschaft
GW Pharmaceuticals plc
Hollis-Eden Pharmaceuticals, Inc.
Enzo Biochem, Inc.
Ligand Pharmaceuticals Incorporated
Mesoblast Ltd
PROLOR Biotech, Inc.
Oramed Pharmaceuticals, Inc.
Orchid Chemicals & Pharmaceuticals Ltd
ConjuChem Biotechnologies Inc.
Lexicon Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc.
Flamel Technologies S.A.
CSL Limited
ProteoTech, Inc.
Yuhan Corporation
Theratechnologies Inc.
Immuron Limited
IPCA Laboratories Limited
Lipoxen PLC
LG Life Sciences, Ltd
Transition Therapeutics Inc.
SemBiosys Genetics Inc.
Uni-Bio Science Group Ltd.
Panacea Biotec Limited
Summit Corporation plc
Phynova Group Ltd
DiaMedica Inc.
NeuroVive Pharmaceutical AB
Debiopharm Group
Advinus Therapeutics Pvt. Ltd.
Betagenon AB
Chipscreen Biosciences Ltd
ActogeniX NV
Camurus AB
Sirtris Pharmaceuticals, Inc.
Metabolex, Inc
Celon Pharma Sp. z o.o.
Cortendo Invest AB
Spherix Incorporated
Arisaph Pharmaceuticals, Inc.
AngioChem Inc.
Allozyne, Inc.
Metabolic Solutions Development Co.
Catabasis Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc.
Five Prime Therapeutics, Inc.
Melior Discovery, Inc.
Diabetology Limited
Braasch Biotech LLC
Intarcia Therapeutics, Inc.
Theracos, Inc.
Versartis, Inc.
Kainos Medicine, Inc.
Nordic Bioscience a/s
Virobay Inc.
Avaxia Biologics, Inc.
Janssen Pharmaceutica, Inc.
Intercept Pharmaceuticals, Inc.
Omeros Corporation
Transtech Pharma, Inc.
Targacept, Inc.
N-Gene Research Laboratories, Inc.
Obio Pharmaceutical Holdings Limited.
ChemoCentryx, Inc.
USV Limited.
Verva Pharmaceuticals Limited
Exsulin Corporation
Medestea Research & Production S.p.A.
NasVax Ltd.
Stelic Institute & Co.
Vybion, Inc.
Regulus Therapeutics Inc.
Esperion Therapeutics, Inc.
Sihuan Pharmaceutical Holdings Group Ltd.
NGM Biopharmaceuticals, Inc.
The Alize Pharma Group
Ardelyx, Inc.
Heptares Therapeutics Ltd.
Receptos, Inc.
MicroDose Therapeutx, Inc.
Sirona Biochem Corp
XBiotech USA, Inc.
Connexios Life Sciences Pvt. Ltd.
Serometrix, LLC
PharmaIN Corporation
Stempeutics Research Private Limited
SignPath Pharma Inc

To view the table of contents for this market research report please visit